The immunologic effects of maraviroc intensification in treated HIV-infected individuals with incomplete CD4+ T-cell recovery: a randomized trial.
about
Maraviroc: a review of its use in HIV infection and beyondInfluence of immune activation and inflammatory response on cardiovascular risk associated with the human immunodeficiency virusHIV and aging: emerging research issuesA Review of Management of Inflammation in the HIV PopulationEffects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Naïve to Antiretroviral Therapy: A Pilot Randomized TrialSystemic effects of inflammation on health during chronic HIV infectionHIV-infected individuals with low CD4/CD8 ratio despite effective antiretroviral therapy exhibit altered T cell subsets, heightened CD8+ T cell activation, and increased risk of non-AIDS morbidity and mortality.A Randomized Placebo Controlled Trial of Aspirin Effects on Immune Activation in Chronically Human Immunodeficiency Virus-Infected Adults on Virologically Suppressive Antiretroviral Therapy.Inflammation, Immune Activation, and Antiretroviral Therapy in HIVImmunologic Effects of Maraviroc in HIV-Infected Patients with Severe CD4 Lymphopenia Starting Antiretroviral Therapy: A Sub-Study of the CADIRIS Trial.Maraviroc intensification in patients with suppressed HIV viremia has limited effects on CD4+ T cell recovery and gene expression.Residual immune dysregulation syndrome in treated HIV infection.Can early therapy reduce inflammation?Gut epithelial barrier dysfunction and innate immune activation predict mortality in treated HIV infection.Glucocorticoid treatment at moderate doses of SIVmac251-infected rhesus macaques decreases the frequency of circulating CD14+CD16++ monocytes but does not alter the tissue virus reservoir.Interactions of HIV and drugs of abuse: the importance of glia, neural progenitors, and host genetic factors.A Phase 1 Randomized, Open Label, Rectal Safety, Acceptability, Pharmacokinetic, and Pharmacodynamic Study of Three Formulations of Tenofovir 1% Gel (the CHARM-01 Study).Maraviroc Intensification of cART in Patients with Suboptimal Immunological Recovery: A 48-Week, Placebo-Controlled Randomized TrialLess Bone Loss With Maraviroc- Versus Tenofovir-Containing Antiretroviral Therapy in the AIDS Clinical Trials Group A5303 Study.A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of a Chemokine Receptor 5 (CCR5) Antagonist to Decrease the Occurrence of Immune Reconstitution Inflammatory Syndrome in HIV-Infection: The CADIRIS StudyVirologic and immunologic effects of adding maraviroc to suppressive antiretroviral therapy in individuals with suboptimal CD4+ T-cell recovery.Protection Against Rectal Chimeric Simian/Human Immunodeficiency Virus Transmission in Macaques by Rectal-Specific Gel Formulations of Maraviroc and Tenofovir.Markers of HIV reservoir size and immune activation after treatment in acute HIV infection with and without raltegravir and maraviroc intensification.Inflammation, immune activation, and cardiovascular disease in HIV.Pathophysiology and management of cardiovascular disease in patients with HIVAntiretroviral therapy in HIV-1-infected individuals with CD4 count below 100 cells/mm3 results in differential recovery of monocyte activation.Immunological and pharmacological strategies to reactivate HIV-1 from latently infected cells: a possibility for HIV-1 paediatric patients?Lack of prophylactic efficacy of oral maraviroc in macaques despite high drug concentrations in rectal tissuesMaraviroc Intensification Improves Endothelial Function in Abacavir-Treated Patients, an Open-Label Randomized Cross-Over Pilot StudyMaraviroc as intensification strategy in HIV-1 positive patients with deficient immunological response: an Italian randomized clinical trial.Serious Non-AIDS events: Immunopathogenesis and interventional strategies.Effect of maraviroc intensification on HIV-1-specific T cell immunity in recently HIV-1-infected individuals.Genetic signatures of HIV-1 envelope-mediated bystander apoptosis.A novel bivalent HIV-1 entry inhibitor reveals fundamental differences in CCR5-μ-opioid receptor interactions between human astroglia and microglia.Immunodiscordant responses to HAART--mechanisms and consequences.Inflammatory co-morbidities in HIV+ individuals: learning lessons from healthy ageing.Residual inflammation and viral reservoirs: alliance against an HIV cure.Ageing with HIV: a multidisciplinary review.Serious Non-AIDS Events: Therapeutic Targets of Immune Activation and Chronic Inflammation in HIV InfectionPersistent HIV-1 replication during antiretroviral therapy.
P2860
Q26778504-30FEF8E0-F01E-4FB7-AE9F-4C691C7A14C0Q26851535-7B872E29-4B2E-4E95-8E06-806304F0ED97Q27016011-3D0A8BEA-59CF-492A-869E-129CE3F34C08Q28078962-AA312063-F022-4429-89FE-E23929E0CA54Q28552729-AD440D77-E552-47A7-9A0F-5B0D7A1D3929Q33577551-C1260AAE-1CE8-4458-9112-7D7C55CDE132Q33618542-F2A6890E-23DE-472B-8A17-855B228646EFQ33629231-BBD09789-DD5B-409F-A126-4F7973DDA666Q33912595-47E21CAD-023A-40B9-8E75-9C5D30C975BCQ33919900-BC80DA8C-7557-4B90-8726-45898C461ED9Q33976854-743FEF75-AD86-4EBB-97E4-5F083C7F8ABEQ34020121-DE7DFE0D-0BD3-41ED-9B39-4D33B0AAAB00Q34159822-47CD5815-46C4-4D1F-9BEF-D7AA901FCBACQ34315572-6C2827BF-8A9D-4AFA-B5F1-F1A11F5CE12DQ34870353-4D8669E4-A53B-4424-AE6C-A13F27218719Q35007339-218215DC-8E84-4C3C-9636-3A8975CDF458Q35571216-0947A41D-DD82-4809-B56B-72195B0F557EQ35712284-2F99C3AE-232B-42FA-89A9-14AD5D1D03B4Q36030485-53FE2C36-4F68-46A5-AE89-F3FB3BD12234Q36041006-8EEE0C9C-2841-4EC3-8424-4B66B2828287Q36263361-1970D429-8214-497D-8BB9-B08A462EEEAFQ36306935-B010B8E0-361E-4C3F-8682-212274D042ACQ36509593-E2B23688-0F82-46A0-955C-07D3965FABE3Q36957752-7C60E750-0E94-49CB-B53B-623B3ACBEBFFQ37038775-854FD539-6AB2-45B6-8329-8823B133F0DBQ37098066-EA34711F-37AE-4E1E-9B22-74C31CE016A7Q37098356-B891FDED-CD87-4AEC-B39D-5D7A8F5F1E19Q37123335-D1478F11-7F98-4F44-86AC-2915F7733339Q37250180-EB751A9F-A6A9-4805-852C-6388CFBD0A44Q37308894-85FAD624-A6C5-4E1B-801D-752E63E1E667Q37418140-C3386551-13B2-4818-A63A-AC84ABBF1712Q37521828-4ABA7DD8-A6F2-4103-A181-C57701D839A4Q37536431-A0CE6EBC-6F3A-49DA-B55A-FEB5984F822CQ37570243-D20B7A0C-B4BC-44E1-BF9B-FAE1172E4085Q38156230-E6C45794-0708-49A6-BE04-8AE589A47918Q38177684-EC13DA73-B0B6-4E69-8A05-8058C6EC85BAQ38269458-07341A99-B24A-495A-B631-A58A1173829FQ38490362-56D2DFE1-1EEF-449E-B592-509CBC374CE7Q38749963-7A28D2A0-29B0-4156-A4B0-CE0B53442A1BQ38808266-4C141BA7-B061-4438-928E-0637F0524F14
P2860
The immunologic effects of maraviroc intensification in treated HIV-infected individuals with incomplete CD4+ T-cell recovery: a randomized trial.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
The immunologic effects of mar ...... recovery: a randomized trial.
@en
type
label
The immunologic effects of mar ...... recovery: a randomized trial.
@en
prefLabel
The immunologic effects of mar ...... recovery: a randomized trial.
@en
P2093
P2860
P50
P1433
P1476
The immunologic effects of mar ...... recovery: a randomized trial.
@en
P2093
Alan L Landay
Brian Clagett
Bridget McLaughlin
Jeffrey N Martin
Lee E Gilman
Ma Somsouk
Michael M Lederman
Nancy S Shulman
Oluwatoyin Adeyemi
Peter W Hunt
P2860
P304
P356
10.1182/BLOOD-2012-06-436345
P407
P577
2013-04-15T00:00:00Z